Elonva (corifollitropin alfa) is considered relevant in clinical settings that involve acute or unstable symptom patterns associated with reproductive health. The medication is primarily applied across domains where additional symptomatic support is needed in the context of Assisted Reproductive Technology (ART).

Its key therapeutic uses fall into conditions presenting with systemic or localized discomfort. Specifically, the medicine is applied in addressing conditions characterized by periods of heightened symptoms (such as infertility treatment) via Controlled Ovarian Stimulation (COS) in women undergoing an ART program, and for managing hypogonadotropic hypogonadism in adolescent males aged 14 and older.

The support provided by this medication contributes to improved comfort during periods of heightened symptoms. It helps ease distress and assists with maintaining functional stability for those participating in an ART program. This makes it relevant for easing symptoms that interfere with daily functioning and those linked to organ-specific functional stress.

The application for adolescent males (aged 14 and older) further supports general well-being during symptomatic phases related to systemic imbalance.

---

Quick Fact: Supports Symptoms that Create Noticeable Physiological Strain

Regulatory References

1. European Medicines Agency Product Information

Official Eligibility and Contraindications

Elonva (corifollitropin alfa) is indicated for women of reproductive age participating in an Assisted Reproductive Technology (ART) program for Controlled Ovarian Stimulation (COS), specifically when using a GnRH antagonist protocol. Use is defined by official regulatory documents through a number of strict exclusions and restrictions.

Contraindicated Populations (Must Not Use):

• Women with tumors of the ovary, breast, uterus, pituitary gland, or hypothalamus.
• Women who are pregnant or breastfeeding.
• Individuals with hypersensitivity to the active substance or excipients.
• Women with primary ovarian failure (high endogenous gonadotrophin levels).
• The presence of ovarian cysts or enlarged ovaries (not due to PCOS) or malformations of the reproductive organs and fibroid tumors incompatible with pregnancy.
• Those with risk markers for severe Ovarian Hyperstimulation Syndrome (OHSS), including a history of OHSS or a basal antral follicle count greater than 20.

Populations Requiring Special Consideration:

• Use is not recommended for women with renal insufficiency or in combination with a GnRH agonist protocol.
• Women with Polycystic Ovarian Syndrome (PCOS) or other known risk factors for a high ovarian response must be closely observed.
• Women older than 36 years of age who weigh less than 50 kg were not studied.

Interactions with other medicines and products

Official regulatory information for Elonva (corifollitropin alfa) primarily focuses on the sequencing of co-administered hormonal agents and the absence of anticipated metabolic interactions.

Interacting Medicinal Products/Categories	Interaction-Related Restrictions and Requirements
FSH-Containing Products	After the single injection of Elonva, no additional follicle-stimulating hormone (FSH) containing product should be administered prior to stimulation day 8.
GnRH Agonist Protocol	The use of Elonva in combination with a Gonadotrophin-Releasing Hormone (GnRH) agonist protocol is not recommended due to limited data suggesting a potentially higher ovarian response.
Cytochrome P450 (CYP) Enzymes	No metabolic interactions with other medicinal products are anticipated because corifollitropin alfa is not a substrate of cytochrome P450 enzymes.

Population-Specific Constraint:

• The use of Elonva is not recommended in women with renal insufficiency (mild, moderate, or severe), as the rate of elimination of corifollitropin alfa may be reduced in this population.

The official labeling establishes constraints based on its mechanism and prolonged action. The primary restriction is procedural, mandating a specific interval before other FSH products can be introduced into the treatment cycle. The regulatory documentation explicitly rules out certain pharmacokinetic interactions, stating that no interaction studies have been performed but none are anticipated due to the drug's non-reliance on CYP450 metabolism.

Specific FSHR Agonism and Cascade Initiation

The action of Corifollitropin alfa begins with its highly specific full agonism at the Follicle-Stimulating Hormone Receptor (FSHR) on ovarian granulosa cells. This targeted binding triggers a classic G s-protein o cAMP signaling cascade, initiating the cellular proliferation and steroidogenesis (hormone production) necessary for follicular development.

⏳ Structural Basis for Sustained Stimulus

The molecule contains a fused Carboxy-Terminal Peptide (CTP) of hCG, which alters its interaction with clearance pathways and results in a prolonged plasma half-life. This structural engineering maintains a steady concentration of the FSHR agonist for seven days.

Physiological Consequence: Continuous Follicular Development

The persistent FSHR agonism achieved through the long-acting structure overrides the feedback mechanisms that typically suppress follicle development, promoting the sustained development of multiple ovarian follicles. Crucially, the mechanism is highly selective, confining its action only to the FSHR pathway, and is thus mechanistically constrained from performing LHR-dependent signaling responses.

Administration of Elonva

Elonva is administered as a single subcutaneous injection. This medication is specifically designed for use in women undergoing fertility treatment to stimulate the development of multiple follicles in the ovaries.

Treatment Procedure

Treatment with this medication is typically initiated at the beginning of the menstrual cycle. The injection is usually performed by a healthcare professional, such as a doctor or nurse. In some instances, the healthcare provider may determine that the patient or their partner can perform the injection themselves. This occurs only after thorough training has been provided to ensure the procedure is completed correctly.

Injection Site and Process

The injection is most commonly administered into the fatty tissue just under the skin, typically in the abdominal area below the navel.

Coordination with Other Medications

In a typical treatment cycle, Elonva replaces the daily injections of follicle-stimulating hormone (FSH) that are usually required for the first seven days of ovarian stimulation. Following this initial seven-day period, a healthcare provider will evaluate the ovarian response to determine if further stimulation with daily FSH injections is necessary to achieve the desired follicle maturity.

Monitoring during Use

Throughout the process, regular monitoring is conducted to track the progress of follicle development. This monitoring generally involves ultrasound examinations and blood tests to measure hormone levels.

Research Evidence / Overview of Studies for Elonva (Corifollitropin Alfa)

Evidence for Use in Controlled Ovarian Stimulation (COS) for ART

The primary evidence for the use of Corifollitropin alfa in women undergoing Assisted Reproductive Technology (ART) comes from multiple large-scale Randomized Controlled Trials (RCTs). These studies were structured to compare a single injection of the medicine (whose single administration was observed to cover the initial seven days of stimulation) against the standard treatment of daily injections of recombinant Follicle-Stimulating Hormone (rFSH). The research was generally conducted using a GnRH antagonist protocol.

The main focus of these studies was to monitor ovarian response and subsequent pregnancy-related outcomes. For women with an Expected Normal Ovarian Response, the findings from these large comparative trials reported that the single-injection regimen resulted in measurements of oocyte retrieval and pregnancy outcomes that were considered comparable to the daily rFSH treatment. Research contributed to the evidence base exploring whether initial ovarian stimulation could be sustained with a single dose.

Evidence in Adolescent Males with Hypogonadotropic Hypogonadism (HH)

Research has also explored the use of this medicine in a specific population of adolescent males (aged 14 years and older) diagnosed with Hypogonadotropic Hypogonadism (HH). The evidence in this population comes from long-term, non-comparative trials. Researchers studied outcomes related to pubertal development, with a primary focus on the measured increase in Testicular Volume and changes in hormonal markers. The findings from these single-group studies reported an observed increase in testicular size and hormonal changes over the study period.

What is Still Uncertain in the Research Landscape

Research highlights areas where further study is needed or where evidence is currently restricted. The most significant gap noted by reviewers is the limited information regarding the drug's use in women undergoing COS who are using a GnRH agonist protocol. Additionally, findings related to specific groups, such as women with Poor Ovarian Response, are based on smaller, often non-comparative trials, meaning the research provides context but does not determine whether an individual in these groups will respond similarly. In all cases, findings describe group patterns, not personal outcomes.

Key Studies & References

1. Corifollitropin Alfa Compared to Daily Recombinant FSH in in Vitro Fertilization Programmes: A Meta-Analysis of Randomized-Controlled Trials

Common questions about Elonva (FAQ)

Q: What if I miss the first day of my period/stimulation to take the injection?

A: If the date your doctor instructed you to take the Elonva injection is missed, the recommended procedure is to contact your doctor or fertility clinic for guidance. Official product information cautions against injecting the medicine without first receiving advice from your physician, as the timing of administration is critical to the treatment cycle.

Q: What are the most common side effects of Elonva?

A: According to official regulatory documents, common side effects are those that may affect up to 1 in 10 patients. These can include headache, nausea, tiredness/fatigue, pelvic pain or discomfort, breast tenderness, and a documented risk of Ovarian Hyperstimulation Syndrome (OHSS).

Q: What is the difference between Elonva and standard daily FSH injections?

A: Elonva is classified as a long-acting form of Follicle Stimulating Hormone (FSH). Its unique structure is intended to provide continuous follicular stimulation for seven days following a single injection. This single-dose capability is designed to cover the stimulation that typically requires the first seven consecutive days of standard daily FSH injections.

Q: What should I do with the used syringe after injection?

A: Regulatory disposal guidelines specify that the used pre-filled syringe and any remaining medicinal product should not be disposed of in household waste. Patient information indicates the syringe should be placed in an appropriate sharps disposal unit or handled according to local requirements for pharmaceutical waste.

Q: How should I prepare the Elonva injection?

A: Elonva is supplied as a sterile solution in a ready-to-use pre-filled syringe. As a pre-filled device, it requires minimal preparation. The specific steps for handling, such as checking the liquid or removing the cap, are detailed in the Patient Information Leaflet (PIL) provided with the medication.

Q: Does Elonva affect the chances of having twins or multiple babies?

A: Multiple pregnancies (such as twins or triplets) are a documented risk associated with all treatments involving gonadotropin hormones, including Elonva. In an Assisted Reproductive Technology (ART) cycle, the chance of multiple births is primarily linked to the number of embryos transferred during the procedure.

Storage and Disposal Instructions for Elonva (Corifollitropin Alfa)

Elonva must be stored under specific conditions to ensure its stability, as outlined in official regulatory labeling.

---

Storage Conditions

Elonva requires storage in a refrigerator at a temperature between 2 C and 8 C (36°F to 46°F). It is mandatory to not freeze the product. The pre-filled syringe must be kept in the original outer carton until use to protect it from light.

Stability Note: The product may be stored outside of the refrigerator at or below 25 C (77°F) for a single period of not more than one month; if this limit is exceeded, the syringe must be discarded.

The medicine must be kept out of the sight and reach of children.

---

Disposal Requirements

Unused or expired Elonva, along with the used syringe and any related waste material, must not be disposed of in household waste or via wastewater. Disposal must be carried out in accordance with local pharmaceutical waste requirements.